Echinacea Blends and Your Liver Enzymes
Echinacea angustifolia and Echinacea purpurea, the narrow-leaved and purple coneflowers, their alkylamides, echinacoside and cynarin, and why a 60:40 root blend behaves differently in the liver.
The episode reads the Institute's two 2026 monographs. A bottle labelled only echinacea leaves out the species, the plant part and the chemistry, which matters because the two roots are chemically unalike. E. angustifolia is a short prairie plant of the central Great Plains whose medicine sits in the taproot, so harvesting kills the plant, and wild stands are in decline; E. purpurea is farmed at scale in Europe. Neither grows wild in Australia, so the whole local supply is imported. A 2020 Italian field trial planted 65 seed accessions labelled as E. angustifolia from germplasm banks, botanic gardens and suppliers: 17 failed to establish and seven of the 48 survivors were other species or hybrids.
Authentication fills the middle. Under the microscope E. angustifolia root shows lignified fibre bundles bordered by black phytomelanin and oleoresin canals; E. purpurea shows none. HPLC under the European Pharmacopoeia requires at least 0.5% echinacoside, with cynarin present to rule out E. pallida, and any cichoric acid in an angustifolia batch gives away purpurea root cut into it. An assay marker is then separated from an active constituent: echinacoside is stable, measurable and degrades with poor drying, so it checks handling, while the alkylamides behind the tingle the eclectics chewed for are what reaches the blood.
Chapters
00:00 A bottle with a purple coneflower on the label
01:29 Two species, one name
02:55 What a label leaves out
04:20 No wild stands here: an imported supply
05:47 The 2020 Italian seed trial
07:12 Cross-pollination in the daisy family
08:46 Phytomelanin under the microscope
11:38 HPLC and the echinacoside limit
13:05 Cynarin, and keeping E. pallida out
14:32 The eclectics and the tingling tongue
15:59 Parthenium integrifolium, the old counterfeit
17:25 Assay marker against active constituent
18:52 Tier C for either root on its own
20:22 The Turner rhinovirus challenge trial
21:47 Barrett 2010, and a p value of 0.08923:14 The long-haul flight trial
24:45 Trial doses against clinical doses
26:10 Why the blend is 60:4027:37 What never reaches the bloodstream
29:02 Alkylamides and CB2 receptors
30:28 First-pass metabolism and CYP3A431:54 Mechanism-based inactivation
34:48 Narrow therapeutic margin medicines
36:13 Asteraceae allergy and atopy
37:38 Anaphylaxis and a 21-year Australian review
39:03 The TGA andrographis investigation
40:28 Echinacea's own signal in the reports
41:56 The warning, and when it is an emergency
43:22 What the eclectics used the root for
46:15 Closing thought
More from the Institute's Journal: https://www.australian-pharmacognosy.org/pharmacopoeia/echinacea-angustifolia/
Nothing in this episode is a prescription or a dose. If you want to use a herb, consult a degree-qualified herbalist with competencies and adequate training in pharmacognosy.
Dr Luke Iggulden, Chief Scientific Officer, made the episode from the Institute's Journal and monograph material. Jesse Kirby, Head of Community Outreach, wrote the show notes and chapters from the episode transcript. Jesse Kirby scheduled the release.
Australian Institute of Pharmacognosy, Cardwell, Queensland.